Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

Add To Watchlist

Recent & Breaking News (TSX:ONC)

Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium

Canada NewsWire November 17, 2020

Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results

Canada NewsWire November 11, 2020

Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting

Canada NewsWire November 9, 2020

Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting

Canada NewsWire November 9, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

Canada NewsWire November 6, 2020

Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

Canada NewsWire October 27, 2020

Clinical Trials Delivering New Optimism in Fight Against Triple-Negative Breast Cancer

Livemoney October 22, 2020

Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board

PR Newswire October 19, 2020

New Report Projects Immunotherapy Drug Market to Reach $274.6 Billion by 2025 with CAGR of 11.0%

Livemoney October 7, 2020

Oncolytics Biotech® to Participate in BIO Investor Forum Digital

PR Newswire October 7, 2020

Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

Canada NewsWire September 1, 2020

(LD Micro) 360 Companies Set to Present this Week

Accesswire August 31, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

PR Newswire August 26, 2020

Billions Pouring Into Drugs That Could Treat Cancer Patients with High TROP2 Expressions

Livemoney August 25, 2020

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

PR Newswire August 10, 2020

Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights

Canada NewsWire August 4, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

Canada NewsWire July 29, 2020

New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight

Livemoney July 21, 2020

New Drug Developments and Combinations Aiding Badly Neglected Triple-Negative Breast Cancer Patients

Livemoney July 15, 2020

Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

PR Newswire June 25, 2020